Twist Bioscience And Ginkgo Bioworks Announces Revision In Its Three-Year $15M Collaboration Including Ginkgo Receiving Preferential Pricing With No Required Minimum Purchase Volume

New terms provide Twist with key license to long DNA technology and assets

Ginkgo to continue ordering from Twist with no purchase minimums

Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508352416/en/

Under the terms of the revised three-year $15 million agreement, Ginkgo will continue to be a valued customer of Twist and will prepay annually for orders of Twist's high-quality DNA products, underscoring the enduring value and reliability of Twist's synthesis capabilities. Ginkgo will receive preferential pricing for DNA products with no required minimum purchase volume. As credit against the agreement signed in 2022, Twist receives licenses and assignments for certain long DNA and other technology as well as related reagents to complement its existing DNA synthesis portfolio of products, while Ginkgo retains the rights to practice the IP transferred to Twist. This strategic acquisition complements Twist's existing comprehensive portfolio of DNA synthesis products, further strengthening its position as a leader in the field.

"Ginkgo has been a trusted customer of Twist since the early days of our synbio offering. As our customers proceed along their journeys and adapt their strategies, we continue to find innovative ways to serve them well," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "With the updated agreement, we will continue to supply Ginkgo with DNA and also gain IP for writing long DNA, that gives us optionality to incorporate on our own platform."

"DNA synthesis is a core technology for synthetic biology and we're happy to combine some of our long DNA technology with Twist to hopefully see more and varied offerings in the market," said Jason Kelly, CEO of Ginkgo Bioworks. "Twist has been an amazing and close partner over many years for Ginkgo and this updated agreement enables us to keep that close relationship while having more flexibility in when and how we order DNA from Twist."